3 results
The objective is to assess the feasibility and safety of the Qvanteq*s bioactive coronary Qstent for treatment of stable coronary artery disease patients with de novo coronary artery stenosis in native vessels.
Primary objectives (Dose-escalation Phase):• To evaluate the safety and tolerability, describe the dose-limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD), optimal biological dose (OBD), or highest protocol-defined dose (HPDD…
Primary objectives: - To collect raw measurement data of the urinary bladder region of volunteers with the early prototype of the Bladder Sensor in multiple postural positions to evaluate the detectability of the bladder in the intended users - To…